Full-Time

ERP ALM Solution Architect

Updated on 7/21/2026

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Pune, Maharashtra, India

In Person

Category
Sales & Solution Engineering (1)
Required Skills
REST APIs
DevOps

Get referred to Roche

Find people who can refer or advise you

Requirements
  • Mastery of ALM Transition & Toolsets: Expert-level knowledge of legacy ALM (SolMan, Focused Build, ChaRM, Worksoft, Adonis) paired with the ability to architect migrations to SAP Cloud ALM.
  • 8+ years of Custom Build & Extensibility Expertise: Proven experience in designing custom-built enterprise software or side-by-side extensions. You must demonstrate an "architectural mindset" capable of building bespoke tools when SaaS products offer limited design influence.
  • SDLC & DevOps Proficiency: Deep understanding of ERP change management and transport layers, with a modern approach to API-first design, CI/CD pipelines, and automated release orchestration.
  • Advanced competency in using AI-augmented engineering tools (e.g., GitHub Copilot, SAP Joule, or equivalent) to improve code quality, automate documentation, and design intelligent extensions that bridge functional gaps in standard SaaS offerings
  • Lifecycle Management: Proven track record of managing at least 2–3 full-scale ERP implementation or upgrade lifecycles, specifically focusing on the architectural trade-offs between "Standard" and "Custom" solutions.
  • Strategic Compliance: Solid background in IT Service Management / ITIL, alongside experience in Computerized System Validation (CSV) and ICFR, ensuring custom-built ALM tools meet global regulatory standards.
  • Global Architectural Leadership: Experience working in a large global company, demonstrating the ability to build consensus among diverse stakeholders
  • English Communication: Superior command of the English language (both written and verbal) is essential for collaborating with global stakeholders and presenting complex ALM strategies to leadership.
  • A bachelor's degree in Computer Science or equivalent
Responsibilities
  • Architect the Pivot: Actively evaluate the functional gaps within SAP Cloud ALM and decide where the organization must "Build" rather than "Buy." You will be responsible for the high-level design of custom ALM modules (potentially on SAP BTP or other cloud-native platforms) to ensure our specific business requirements are met.
  • Design the "Requirements to Deploy" Lifecycle and Lead Technical Decisioning: You will orchestrate the end-to-end framework including Business Process Modelling, Requirements, Change, Transport, Release, Test, Defect and System Documentation Management. You are not just a tool user; you are the designer of the framework that enables these processes.
  • Govern Hybrid Landscapes: You will define the integration patterns required to link SAP-specific ALM components with the broader enterprise DevOps toolchain, ensuring a "clean core" strategy while managing the decommissioning of legacy SolMan/ChaRM environments.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Roche targets top-three obesity status by 2030 via CT-388 and petrelintide assets.
  • The $1.5B Poseida acquisition secures off-the-shelf CAR-T therapies for oncology and immunology.
  • AI-driven diagnostics gain traction through the $750M PathAI acquisition closing in 2026 H2.

What critics are saying

  • Kadcyla and Perjeta biosimilar erosion in 2025–2026 will strip billions from oncology revenue.
  • Ocrevus loss of exclusivity in 2029 threatens the entire immunology franchise profitability.
  • Eight cancer drugs face biosimilars by 2030, risking CHF 6.7B sales decline easily.

What makes Roche unique

  • Roche uniquely integrates Pharmaceuticals and Diagnostics under one roof for personalized healthcare.
  • Only Roche combines world-class drug R&D with global diagnostics leadership seamlessly.
  • Roche leverages companion diagnostics to pair targeted therapies with precise patient identification.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

Dealroom.co
Apr 16th, 2026
SAGA company information, funding & investors

SAGA, providing cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor dna (ctdna). Here you'll find information about their funding, investors and team.

Yahoo Finance
Apr 13th, 2026
Roche receives CE mark for Elecsys NfL blood test to detect neuroinflammation in multiple sclerosis

Roche has received CE mark approval for its Elecsys Neurofilament Light Chain blood test to detect neuroinflammation in adults with relapsing remitting multiple sclerosis. The test measures NfL, a protein released during nerve cell injury, providing insight into neuroaxonal damage associated with the disease. Multiple sclerosis affects over 2.9 million people worldwide. Whilst early and regular monitoring is critical, patients often struggle to access routine MRI scans. The minimally invasive blood test offers a more accessible alternative, complementing clinical assessments and potentially enabling earlier intervention. The test runs on Roche's widely available cobas instruments, delivering standardised results and requiring only a simple blood sample. This reduces the need for patients to travel to specialist centres, making frequent monitoring more practical where traditional testing faces geographic, financial or logistical barriers.

Bizwatch
Apr 12th, 2026
Roche invests $20M in degrader-antibody conjugate platform via C4 Therapeutics deal worth up to $1B

Roche has partnered with C4 Therapeutics to develop degrader-antibody conjugates (DACs), marking a $20 million upfront payment with potential milestone payments exceeding $1 billion. The collaboration targets cancer therapeutics using C4's Torpedo platform. DACs represent a next-generation approach to antibody-drug conjugates (ADCs). Whilst ADCs attach cytotoxic drugs to antibodies, DACs use targeted protein degradation payloads to selectively eliminate specific proteins within cancer cells, potentially reducing toxicity and drug resistance whilst accessing previously difficult targets. Amongst Korean listed companies, Orum Therapeutics leads DAC development, having licensed ORM-6151 to Bristol Myers Squibb in 2023. Y-Biologics partnered with Ubix Therapeutics, whilst Oscotec is developing three DAC pipelines through subsidiary Genosco, targeting technology transfers after 2028.

Yahoo Finance
Mar 30th, 2026
Roche gets FDA clearance for cobas c703 and ISE neo lab testing units with 2,000 tests per hour

Roche has received FDA 510(k) clearance for its cobas c703 and cobas ISE neo analytical units, designed to enhance laboratory efficiency through increased automation and testing capacity. The units are part of Roche's cobas pro integrated solutions platform. The cobas c703 delivers up to 2,000 tests per hour with 70 reagent positions, doubling clinical chemistry throughput whilst reducing reagent reloads. The cobas ISE neo provides up to 1,800 tests per hour with automated maintenance, reducing hands-on time and plastic waste compared to previous systems. Both units feature monthly operator maintenance to improve uptime and help laboratories address staffing shortages and growing test volumes. Roche has over 4,000 cobas analysers installed across the United States.

Yahoo Finance
Mar 30th, 2026
Roche launches cobas MPX-E assay, 4-in-1 donor screening test for HIV, HCV, HBV and HEV

Roche has launched the cobas MPX-E assay, a four-in-one donor screening test that simultaneously detects HIV, Hepatitis C, B and E viruses. The test is now available in countries accepting the CE mark. The assay consolidates detection of four major viral targets into a single workflow, improving laboratory efficiency and reducing costs. It features dual-target detection for HIV-1 and enhanced sensitivity for Hepatitis E, which causes an estimated 20 million infections and 70,000 deaths annually worldwide. The test runs on Roche's fully automated cobas x800 systems, which process over 10 million tests monthly across laboratories globally. The ready-to-load reagents enable up to eight hours of walk-away time. The nucleic acid testing blood screening market is valued at approximately 800 million Swiss francs globally, with an expected annual growth rate of 2% through 2029.